Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5236400 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Intranasal administration of recombinant human BDNF as a potential therapy for some primary headaches.
J Headache Pain
October 2024
Dompé Farmaceutici SpA, Via Santa Lucia 6, 20122, Milano, Italy.
Article Synopsis
- BDNF plays an important role in brain function and may help with pain and depression; this study tested its effectiveness against migraines using an animal model.
- Researchers administered two doses of recombinant human BDNF (rhBDNF) to rats with pain induced by NTG injections, measuring pain response and changes in brain-related neuropeptides and cytokine levels.
- Results showed that rhBDNF significantly reduced migraine-related pain and altered gene expression similarly to the migraine medication sumatriptan, indicating its potential as a non-invasive migraine treatment.
Chronic Recurrent Multifocal Osteomyelitis Involving the Spine, Sternum, and Lower Extremities: A Case Report.
Pediatrics
October 2024
Department of Allergy, Immunology, and Rheumatology, University of Florida, Gainesville.
Article Synopsis
- - Chronic recurrent multifocal osteomyelitis (CRMO) is a nonbacterial bone disease in children that can be mistaken for infections or tumors, making early diagnosis and treatment crucial
- - A 10-year-old boy experienced pain and swelling in his ankle; initial tests were inconclusive, but four years later, he showed similar symptoms, leading to further imaging and biopsies that confirmed CRMO
- - The boy was treated with medications like celecoxib and infliximab, resulting in improved symptoms and remission over two years, although he developed a skin condition called palmoplantar pustular psoriasis that is often associated with CRMO
Chlorpyrifos-oxon induced neuronal cell death via endoplasmic reticulum stress-triggered apoptosis pathways.
Toxicol In Vitro
December 2024
Bioelectromagnetics Key Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China; Institute of Environmental Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China. Electronic address:
Chlorpyrifos (CPF) is one of the organophosphorus pesticides widely used throughout the world. Epidemiological studies suggested a link between CPF exposure and neurologic disorders, while the molecular mechanisms remain inconclusive. In the present study, we investigated the impacts of chlorpyrifos-oxon (CPO), the major toxic CPF metabolite, on cell apoptosis, and explored possible mechanism associated with endoplasmic reticulum (ER) stress in SH-SY5Y cells.
View Article and Find Full Text PDFEffective strategies for managing trimethoprim-sulfamethoxazole and levofloxacin-resistant Stenotrophomonas maltophilia infections: bridging the gap between scientific evidence and clinical practice.
Curr Opin Infect Dis
December 2024
Médecine Intensive Réanimation, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière.
Article Synopsis
- The review outlines challenges in treating difficult-to-treat strains of Stenotrophomonas maltophilia (Sma), particularly those resistant to standard antibiotics like trimethoprim-sulfamethoxazole and fluoroquinolones.
- Recent findings indicate that current antibiotic breakpoints may underestimate the prevalence of these resistant strains, highlighting the need for better treatment strategies.
- While cefiderocol and an aztreonam-L2 inhibitor combination show promise, their clinical efficacy is still uncertain, and further comparative studies are essential to guide treatment decisions effectively.*
The dual role of FSP1 in programmed cell death: resisting ferroptosis in the cell membrane and promoting necroptosis in the nucleus of THP-1 cells.
Mol Med
July 2024
Department of Physiology, Clinical Anatomy and Reproductive Medicine Application Institute, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Article Synopsis
- Acute monocytic leukemia-M5 (AML-M5) is difficult to treat, with high morbidity and a poor prognosis, highlighting the importance of programmed cell death (PCD) in its treatment.
- The study investigates the effects of treating THP-1 cells with Erastin and IMP-366, discovering that inhibiting myristoylation leads to increased ferroptosis and necroptosis, characterized by specific cellular changes like lipid peroxidation and mitochondrial swelling.
- Findings indicate that targeting FSP1 can switch the cell death pathways in AML-M5, suggesting new therapeutic strategies could be developed to combat this aggressive form of leukemia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!